Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.

Bühler, A; Wendtner, C-M; Kipps, T J; Rassenti, L; Fraser, G A M; Michallet, A-S; Hillmen, P; Dürig, J; Gregory, S A; Kalaycio, M; Aurran-Schleinitz, T; Trentin, L; Gribben, J G; Chanan-Khan, A; Purse, B; Zhang, J; De Bedout, S; Mei, J; Hallek, M; Stilgenbauer, S

Bühler, A; Wendtner, C-M; Kipps, T J; Rassenti, L; Fraser, G A M; Michallet, A-S; Hillmen, P; Dürig, J; Gregory, S A; Kalaycio, M; Aurran-Schleinitz, T; Trentin, L; Gribben, J G; Chanan-Khan, A; Purse, B; Zhang, J; De Bedout, S; Mei, J; Hallek, M; Stilgenbauer, S.

Affiliation

Bühler A; Department of Internal Medicine III, Ulm University, Ulm, Germany.
Wendtner CM; Klinikum Schwabing, Academic Teaching Hospital of University of Munich, Munich, Germany.
Kipps TJ; Department I of Internal Medicine, University of Cologne, Cologne, Germany.
Rassenti L; University of California San Diego Moores Cancer Center, La Jolla, CA, USA.
Fraser GA; University of California San Diego Moores Cancer Center, La Jolla, CA, USA.
Michallet AS; McMaster University, Juravinski Cancer Centre, Hamilton, ON, Canada.
Hillmen P; Hospices civils de Lyon, Centre Hospitalier Lyon Sud, Lyon, France.
Dürig J; St James's Institute of Oncology, Leeds, UK.
Gregory SA; University Hospital Essen, Essen, Germany.
Kalaycio M; Rush University Medical Center, Chicago, IL, USA.
Aurran-Schleinitz T; Cleveland Clinic, Cleveland, OH, USA.
Trentin L; Institut Paoli Calmettes, Marseille, France.
Gribben JG; Padua University School of Medicine, Padua, Italy.
Chanan-Khan A; Barts Cancer Institute, Queen Mary, University of London, London, UK.
Purse B; Mayo Clinic, Jacksonville, FL, USA.
Zhang J; Celgene Corporation, Summit NJ, USA.
De Bedout S; Celgene Corporation, Summit NJ, USA.
Mei J; Celgene Corporation, Boudry, Switzerland.
Hallek M; Celgene Corporation, Summit NJ, USA.
Stilgenbauer S; Department I of Internal Medicine, University of Cologne, Cologne, Germany.

Blood Cancer J ; 6: e404, 2016 Mar 11.

Article de En | MEDLINE | ID: mdl-26967821

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Thalidomide / Leucémie chronique lymphocytaire à cellules B / Résistance aux médicaments antinéoplasiques / Facteurs immunologiques / Antinéoplasiques Type d'étude: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Aged / Aged80 / Female / Humans / Male / Middle aged Langue: En Journal: Blood Cancer J Année: 2016 Type de document: Article Pays d'affiliation: Allemagne Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google